Company Overview
Snapshot
Founded in March 2022 by Roy Rabinowitz and Omer Stoller, Kanso Diagnostics operates with 1–10 employees. The company has raised $1.5M across three funding rounds from two investors. In June 2023, Peregrine Ventures led a Seed funding round.
Business overview
Kanso Diagnostics is developing a molecular testing platform for the diagnosis of bacterial and viral infections. Its core technology aims to transform contemporary diagnostics by providing PCR-grade accuracy with rapid home testing convenience, detecting multiple pathogens and genetic biomarkers from a single sample. The company's solution minimizes diagnosis time from days to minutes, facilitating at-home medical testing and ensuring accessibility and ease of use. Kanso Diagnostics operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Diagnostics Devices, and Biotechnology.
Strategic signal
In January 2025, Kanso Diagnostics garnered significant media attention from Haaretz and TheMarker, highlighting its molecular testing platform as "Faster, Simpler, Better." This widespread coverage signals growing market recognition and validation of the company's innovative approach to diagnostics, suggesting a positive trajectory for adoption and strategic partnerships in the health tech landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Kanso Diagnostics' primary focus?
- Kanso Diagnostics focuses on developing a molecular testing platform for the diagnosis of bacterial and viral infections, aiming to provide rapid and accurate results from a single sample.
- When was Kanso Diagnostics founded and by whom?
- Kanso Diagnostics was founded in March 2022 by Roy Rabinowitz and Omer Stoller.
- What was a key funding event for Kanso Diagnostics?
- In June 2023, Kanso Diagnostics secured Seed funding led by.
- What is the total capital raised by Kanso Diagnostics?
- Kanso Diagnostics has raised a total of $1.5M across three funding rounds.
- What is the significance of Kanso Diagnostics' technology?
- Kanso Diagnostics' novel technology offers PCR-grade accuracy for rapid home testing, detecting multiple pathogens and genetic biomarkers from a single sample, thereby reducing diagnosis time from days to minutes.